• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SYRS

    Syros Pharmaceuticals Inc.

    Subscribe to $SYRS
    $SYRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2016

    Exchange: NASDAQ

    Website: syros.com

    Peers

    $CALA
    $IRWD
    $KALA
    $KNSA
    $ATNM
    $OCUP

    Recent Analyst Ratings for Syros Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    9/23/2021$20.00 → $23.00Buy
    Roth Capital
    See more ratings

    Syros Pharmaceuticals Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Haas Jason bought $161,240 worth of shares (100,000 units at $1.61), increasing direct ownership by 407% to 124,552 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      9/12/24 5:00:03 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Chee Conley bought $160,680 worth of shares (100,000 units at $1.61), increasing direct ownership by 444% to 122,504 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      9/12/24 5:00:03 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akkaraju Srinivas bought $3,999,998 worth of shares (904,977 units at $4.42) (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      12/26/23 5:24:30 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syros Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Syros Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Syros Pharmaceuticals with a rating of Buy and set a new price target of $23.00 from $20.00 previously

      9/23/21 9:11:45 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on Syros Pharmaceuticals with a new price target

      Alliance Global Partners reiterated coverage of Syros Pharmaceuticals with a rating of and set a new price target of $14.00 from $18.00 previously

      3/5/21 4:01:58 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syros Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Simonian Nancy A sold $10,016 worth of shares (37,070 units at $0.27), decreasing direct ownership by 90% to 4,000 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      12/4/24 5:00:05 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Simonian Nancy A sold $35,739 worth of shares (134,713 units at $0.27), decreasing direct ownership by 77% to 41,070 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/27/24 5:00:04 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Development Officer Stephens Kristin sold $7,949 worth of shares (36,133 units at $0.22), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:16 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal & Compliance Offic Quirk Gerald E sold $10,321 worth of shares (46,657 units at $0.22), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:12 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Roth David sold $2,382 worth of shares (12,099 units at $0.20), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:14 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Chee Conley sold $26,932 worth of shares (134,797 units at $0.20), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:10 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Haas Jason sold $28,980 worth of shares (137,803 units at $0.21), closing all direct ownership in the company (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/20/24 5:00:07 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Simonian Nancy A converted options into 40,125 shares, increasing direct ownership by 30% to 175,783 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/4/24 5:01:59 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Roth David converted options into 18,875 shares and covered exercise/tax liability with 6,776 shares (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/4/24 5:01:40 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Haas Jason converted options into 18,875 shares and covered exercise/tax liability with 5,624 shares, increasing direct ownership by 11% to 137,803 units (SEC Form 4)

      4 - Syros Pharmaceuticals, Inc. (0001556263) (Issuer)

      11/4/24 5:01:22 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syros Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Syros Pharmaceuticals Inc.

      15-12G - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/20/25 5:01:35 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Syros Pharmaceuticals Inc.

      144 - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      3/14/25 4:43:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:11 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:08 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:05 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:06 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:02 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:04 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Syros Pharmaceuticals Inc.

      EFFECT - Syros Pharmaceuticals, Inc. (0001556263) (Filer)

      3/12/25 12:15:03 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Syros Pharmaceuticals Inc.

      144 - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      3/11/25 5:46:37 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syros Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

      KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA, (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant po

      4/15/25 1:20:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

      Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from the Nasdaq Stock Market ("Nasdaq") and the deregistration of its common stock in order to terminate and suspend the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified Nasdaq of its intention to voluntarily delist its shares of common stock from the Nasdaq Global Select Market. The Company intends to file a Form 25 with the Securities and Exchange Commission ("SEC") to effect the delisting

      2/28/25 4:05:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

      -- SELECT-MDS-1 Did Not Meet its Primary Endpoint -- -- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression did not meet its primary endpoint of complete response (CR) rate. Tamibarotene is Syros' proprietary oral, selective, retinoic acid receptor alpha (RARα) agonist. In the first 190

      11/12/24 4:30:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

      -- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. "It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. We expect to announ

      10/31/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 07454. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 da

      10/24/24 7:08:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial at the Society of Hematologic Oncology (SOHO) Annual Meeting taking place September 4-7, in Houston, Texas. Additionally, Syros announced that company management will participate in the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11 in New York City. Details are as follows: 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) Presentation Title:

      8/27/24 7:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. This decision is based on the results of a prespecified interim analysis of the trial. Data from 51 patients enrolled in SELECT-AML-1 were reviewed on August 9, 2024. This review i

      8/12/24 4:15:00 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update

      -- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update. "Syros is well-positioned heading into key clinical data readouts expected in the second half of 2024, including pivotal complete response (CR) data from the Phase 3 SELECT-MDS-1 trial b

      7/31/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its second quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 64947. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 da

      7/24/24 7:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)

    Syros Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company

      -- Conley Chee, CCO and CBO, to succeed Nancy Simonian, M.D. as CEO; Dr. Simonian to retire as CEO, effective December 1, 2023, and will remain on the Board of Directors -- -- Planned workforce reduction of approximately 35% sharpens focus of organization on late-stage development of tamibarotene in MDS and AML and ongoing pre-launch activities -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced a strategic realignment to prioritize key development and pre-launch activities to advance tamibarotene for the frontline treatment of higher-risk myelodysplastic

      10/2/23 8:45:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

      Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros. "We are pleased to welcome Jason to Syros, who brings an exceptional depth of financial, strategic, and leadership experience in the life sciences space," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Jason has a proven track record as a strategic advisor to biotechnology and pharmaceutical companies across all stages of development. He joins Syros at a pivotal time, as we advan

      10/12/21 8:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Appointment of Conley Chee as Chief Commercial Officer

      Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Conley Chee as the company's first Chief Commercial Officer. Mr. Chee brings 20 years of pharmaceutical sales leadership, marketing and strategy experience in the U.S. and globally, with particular expertise in driving commercial strategy for novel medicines for the treatment of cancer. "We are pleased to welcome Conley to Syros. With multiple programs progressing through late-stage development and towards potential new drug applications in 2024, now is the right time to begin building our commercial organization," said Nancy Simonian, M.D.,

      9/27/21 8:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors

      Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company's Board of Directors. Dr. Dunsire is a highly respected industry veteran with more than 30 years of clinical, commercial, and international management experience within the life sciences industry. "Deborah is a phenomenal leader with a track record of creating value through successful development and commercialization of life-changing new therapies for people with cancer and other serious diseases," said Nancy Simonian, M.D., Chief Executive Officer of Syros. "Her global commercial expertise, oncology R&

      9/10/21 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syros Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:28:08 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:24:48 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/14/24 5:05:24 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      11/12/24 4:30:27 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc.

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      8/2/24 6:39:25 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Syros Pharmaceuticals Inc.

      SC 13G - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      2/14/24 8:56:21 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      2/13/24 8:22:30 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      2/13/24 7:02:26 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      2/13/24 6:59:26 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Syros Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Syros Pharmaceuticals, Inc. (0001556263) (Subject)

      2/9/24 5:08:58 PM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Syros Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials

      KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters: Boston, MA, (Headquarters: Boston, MA; NASDAQ:SYRS), through a mutual agreement. The acquisition was completed on February 26, 2025. Tamibarotene (RN-014) is a retinoic acid receptor agonist for which Rege Nephro is currently conducting a Phase 2 clinical trial in Japan in autosomal dominant po

      4/15/25 1:20:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

      -- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected in Mid-November -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended September 30, 2024 and provided a business update. "It is a very exciting time at Syros, as we approach a significant milestone in our efforts to establish tamibarotene as a potential new standard of care for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. We expect to announ

      10/31/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 31, 2024 to report its third quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 07454. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 da

      10/24/24 7:08:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update

      -- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update. "Syros is well-positioned heading into key clinical data readouts expected in the second half of 2024, including pivotal complete response (CR) data from the Phase 3 SELECT-MDS-1 trial b

      7/31/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its second quarter 2024 financial results and provide a business update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 64947. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 da

      7/24/24 7:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

      -- Three medical experts will join members of Syros' leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the opportunity for tamibarotene on Tuesday, June 25 at 11:00 a.m. ET -- -- Syros expects to report pivotal Phase 3 data from SELECT-MDS-1 by mid-4Q 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to

      6/13/24 7:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

      – Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event with Medical Experts on June 25, 2024 – – Received FDA Fast Track Designation for Tamibarotene for the Treatment of Unfit AML; Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 3Q24 – -- Management to Host Conference Call at 8:30 AM ET Today – Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provid

      5/14/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial (800) 549-8228 (domestic) or (289) 819-1520 (international) and refer to conference ID 16518. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days

      5/7/24 7:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

      -- Completed Enrollment of 190 Patients for Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Also Expected in 2024 -- -- Completed a $45.0 Million Equity Offering, Extending Cash Runway into 2Q 2025 -- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update. "We are entering 2024 poised for a major tr

      3/27/24 7:30:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

      Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update. To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (international) and refer to conference ID 21905455. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for

      3/20/24 7:00:00 AM ET
      $SYRS
      Biotechnology: Pharmaceutical Preparations
      Health Care